Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-First Solar, Iveric Bio, Salesforce
Aptinyx falls on restructuring plan; reports 60% workforce reduction
Brief: Aptinyx Board Approves To Reduce Its Workforce By About 60%
U.S. RESEARCH ROUNDUP-Aptinyx, Eve Holding, Gossamer Bio
U.S. STOCKS ON THE MOVE-Rivian, Meta Platforms, Bioventus
U.S. STOCKS ON THE MOVE-Zoom Video, AMC Entertainment, Target Corp
U.S. STOCKS ON THE MOVE-Twilio, Dentsply Sirona, Kontoor Brands
U.S. STOCKS ON THE MOVE-Target, Chevron, Zoom
Aptinyx falls on dementia drug failing mid-stage study, PTSD drug termination
Brief: Aptinyx Reports Results From Phase 2 Study Of Nyx-458 In Cognitive Impairment And Provides Pipeline And Corporate Update
Brief: Aptinyx Inc - On Dec 7, 2022, Co Received Approval From Nasdaq To Transfer Stock Listing From Nasdaq Global Select Market To Nasdaq Capital Market - Filing
Aptinyx Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aptinyx Reports Third Quarter 2022 Financial Results, Recent Highlights
Aptinyx Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Clinical Evaluation Of Aptinyx's Nyx-783 For Treatment Of Opioid Use Disorder To Be Funded By $5.6 Million Nih Grant